Oct 22 (Reuters) – Vicore Pharma Holding AB: * VICORE PHARMA HOLDING AB: PHASE 2B ASPIRE TRIAL OF BULOXIBUTID IN IPF PASSES PRE-PLANNED FUTILITY ANALYSIS, ON TRACK FOR MID-2027 TOPLINE RESULTS *
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)